Executive Summary
Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cancer over the past 5 years. This is most prominent due to the introduction of three novel cytotoxic agents - Xeloda, Camptosar, and Eloxatin - and the recent approval of the two antibodies - Avastin and Erbitux.
Interestingly, an army of novel agents and targets are currently in Phase II clinical trials, and their contributions and impact on future therapy in colorectal cancer remains to be seen.
Scope of this report
- Thorough examination of status and impact of 70 novel drugs in development
- Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
- Case studies on major CRC drugs on market
- Competitive landscape assessment, including more than 120 companies in the field and high lightening the top twenty competitors
Research and analysis highlights
Colorectal cancer has become an excellent tumor model for evaluating new therapeutic strategies. Development of a detailed understanding of how this cancer develops, spreads, and grows allows a tailored approach to all stages of treatment: prevention, adjuvant treatment, and therapy of advanced disease. As a result, specific molecular processes have been targeted for therapeutic intervention, including growth factor receptors, proliferation signaling, cell cycling, apoptosis, angiogenesis, and the immune system.
The anti-VEGF antibody Avastin has in recent clinical trials been shown to be safely and effectively used in combination with each of the active anticancer agents used in CRC. However, the chdevelopment of active combination regimens has not yet achieved any significant improvements in the actual cure rate.
Intense efforts are attempting to identify critical molecular biomarkers that can be used to predict for either clinical response to chemotherapy and/or targeted therapies and/or the drug-specific side effects. This has led the industry into a multitude of collaborations, for them to have the chance to successfully deliver on these issues.
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for 70 novel therapeutics in CRC, and the results of clinical trials to date.
- Novel targets and agents are discussed organized into: Growth factor receptors, Signaling transducers; Apoptopic agents, Anti-vascular agents and Immuno-modulators.
- Gain insight into the current challenges and commercial opportunities associated with CRC
| 
View Cart
